Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 12/20 | 0.55 |
| ▸ | GHSR | Q92847 | 1/20 | 0.54 |
| ▸ | CD47 | Q08722 | 1/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130526 | 1.00 | IL23R (0.55) | IL23RGHSRCD47C5AR1KISS1R | |
| SCHEMBL30093017 | 0.99 | GHSR (0.55) | IL23RGHSRCD47C5AR1KISS1R | |
| SCHEMBL30092977 | 0.99 | GHSR (0.55) | IL23RGHSRCD47C5AR1KISS1R | |
| SCHEMBL30092959 | 0.97 | IL23R (0.55) | IL23RGHSRCD47KISS1RPRMT1 | |
| SCHEMBL30893567 | 0.97 | KISS1R (0.56) | IL23RGHSRKISS1R | |
| SCHEMBL29732780 | 0.96 | KISS1R (0.54) | IL23RCD47C5AR1KISS1RPRMT1 | |
| SCHEMBL30305322 | 0.96 | KISS1R (0.54) | IL23RCD47C5AR1KISS1RPRMT1 | |
| SCHEMBL30148434 | 0.96 | KISS1R (0.54) | IL23RCD47C5AR1KISS1RPRMT1 | |
| SCHEMBL30456528 | 0.96 | KISS1R (0.54) | IL23RCD47C5AR1KISS1RPRMT1 | |
| SCHEMBL30305637 | 0.96 | KISS1R (0.54) | IL23RCD47C5AR1KISS1RPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | VIP, CUTA, LNPEP | IL23R 2376/4885GHSR 967/4885CD47 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.